Doxycycline
DrugDoxycycline 100 mg orally every 12 hours for 7 days.
NCT Number: NCT07513103
This multicenter, randomized, open-label clinical trial evaluated the efficacy and tolerability of intravenous tigecycline compared with oral doxycycline in adults hospitalized with scrub typhus. Participants were randomly assigned to receive either intravenous tigecycline or oral doxycycline. The primary efficacy outcome was time to defervescence, and tolerability was assessed based on reported adverse events.
Looking for future studies?
Notify Me19 year–100 year
All sexes
Interventional
Not applicable
Dankuk university hospital, Cheonan, Chungcheongnam-do, South Korea
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Doxycycline 100 mg orally every 12 hours for 7 days.
Tigecycline 100 mg intravenously as a loading dose, followed by 50 mg intravenously every 12 hours for 5 days.
Time frame: from treatment initiation to defervescence, assessed daily through Day 7
Time from treatment initiation to defervescence, defined as maintenance of body temperature below 37.3°C for at least 48 consecutive hours without antipyretics.
Time frame: up to 7 days after treatment initiation
persistence of fever over 3 days after therapy, but no other cause of fever
Time frame: up to 30 days after treatment initiation
relapse on 30th days
Time frame: up to 28 days after treatment initiation
Occurrence of treatment-emergent adverse events
Jin Soo Lee
Other
Clinical Efficacy Analysis of Drug Use Tigecycline for Re-creation of Antimicrobial Agents for Treatment of Scrub Typhus.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06675110
Bacterial Infections, Bacterial Infections and Mycoses
Mae Chan, Changwat Chiang Rai, Thailand
View Trial DetailsNCT04506944
Bacterial Infections, Bacterial Infections and Mycoses
Vellore, Tamil Nadu, India
View Trial DetailsNCT02876367
Bacterial Infections, Bacterial Infections and Mycoses
View Trial DetailsNCT02915861
Bacterial Infections, Bacterial Infections and Mycoses
Chiang Rai, Thailand
View Trial Details